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Abstract
Skeletal muscle wasting is a consequence of numerous physiological conditions,
including denervation, corticosteroid treatment, immobilization, and aging. The E3
ubiquitin ligases, MuRF1 and MAFbx, are induced under nearly all atrophy conditions
and are believed to play a key role in protein degradation in atrophying muscle. However,
the preliminary data described in this study provides new evidence that MuRF1 may also
act as a transcriptional modulator of atrophy-induced gene activity, including the
regulation of MAFbx and MuRF1 expression. To characterize the transcriptional
regulation of MuRF1 and MAFbx, reporter gene constructs containing fragments of the
proximal promoter regions of these genes were developed, transfected into C2C12 cells
with or without a MuRF1 expression plasmid and monitored for differences in reporter
gene activity. The MuRF1 and MAFbx reporters each showed repressed activity in cells
ectopically expressing MuRF1 compared to cells that did not overexpress MuRF1.
Furthermore, ectopic expression of the myogenic regulatory factors (MRFs), MyoD1 and
myogenin, caused significant activation of the MuRF1 and MAFbx reporter constructs.
However, co-overexpression of MuRF1 with MyoD1 or myogenin resulted in reversal of
MRF induction of reporter gene activity, and synergistic repression of a constructed Ebox reporter system. To further characterize the role of the MuRF1 gene product in
repression of MuRF1 expression, a MuRF1 RING domain mutant and a MuRF1 cterminal mutant were created. The mutant constructs were then co-transfected along with
MRF expression plasmids and the MuRF1 reporter construct into C2C12 cells and reporter
gene activity was assessed. The MuRF1 RING mutant failed to reverse MRF activation
vii

of the reporter gene, while the c-terminal mutant successfully reversed activation of the
reporter gene. These findings suggest that ubiquitin ligase activity is required for MuRF1
transcriptional regulatory effects. These data offer exciting evidence of a potential new
function for MuRF1 as a transcriptional modulator of atrophy-induced changes in gene
expression.

viii

Chapter 1: Overview of the Role of MuRF1 in Skeletal Muscle Atrophy

Introduction
The goal of this thesis was to provide a better understanding of the transcriptional
regulation of atrophy-induced genes, called atrogenes. Atrogenes are genes commonly
regulated under models of skeletal muscle atrophy, which is caused by a number of
physiological conditions including chronic disease, denervation, immobilization, and
aging.1, 2 Key components of the atrophy pathways have been identified; however, the
role and regulation of these components are not yet fully understood. The Muscle RING
(Really Interesting New Gene) Finger Protein-1 (MuRF1) gene has been identified as a
major effector of skeletal muscle wasting.1 MuRF1 has been classified as an E3-ubiquitin
ligase that tags proteins for destruction by the proteasome.3 MuRF1 is also
transcriptionally up-regulated under virtually all atrophy conditions; however the
mechanism of its regulation is currently incomplete.1 Therefore, the goal of this research
was to further explore the mechanisms by which MuRF1 is transcriptionally regulated
and expand on the role of MuRF1 in the skeletal muscle atrophy signature.
The primary objective of this investigation was to further characterize the
transcriptional regulation of MuRF1, as well as its potential downstream effects,
including the possibility that MuRF1 coordinates a negative feedback mechanism to
transcriptionally down-regulate a subset of atrophy-induced genes, including itself, and a
second E3-ubiquitin ligase, Muscle Atrophy F-box (MAFbx). The data presented herein

demonstrates that the mechanism by which MuRF1 transcriptionally regulates a diverse
array of atrogenes is mediated by direct and/or indirect interaction and modification of
muscle-specific transcription factors, including myogenin and MyoD1. MyoD1 and
myogenin sequentially and transiently associate with the promoters of a wide array of
muscle-specific genes, and are necessary for the development of functional skeletal
muscle and myogenic commitment, respectively.4, 5 MuRF1 and MAFbx expression rise
dramatically during most models of atrophy,1 as does the expression of MyoD1 and
myogenin.6 Furthermore, MyoD1 and myogenin have been shown to be important
regulators of neurogenic atrophy-induced gene expression (i.e. denervation), including
the induction of MuRF1 and MAFbx.6 Our work focused on the cooperative
transcriptional regulation of atrogenes through the interaction of MuRF1 and myogenic
regulatory factors (MRFs), such as MyoD1 and myogenin. Furthermore, the importance
of specific domains of the MuRF1 protein in atrogene regulation was also explored.
Specifically, the role of the RING finger domain and the acidic carboxyl-terminal domain
of the MuRF1 protein in modulating MRF activity were investigated.

MuRF1 as an E3 Ligase In the Ubiquitin-Proteasome Pathway
The findings from this project reveal a potentially new functional role for MuRF1
in the skeletal muscle atrophy cascade. MuRF1 has long been known to be involved in
mediation of muscle atrophy, presumably by targeting proteins for degradation via the
well-characterized ubiquitin-proteasome system (UPS), which is the main mechanism for
degradation of intracellular proteins.7 Briefly, proteins are first marked by the covalent
addition of ubiquitin, a 76 amino acid polypeptide. These tagged proteins are then
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degraded into smaller peptides through proteolysis by the 26S proteasome complex
(Figure 1).

Figure 1. Schematic diagram of the ubiquitin-proteasome system.8

The mechanism by which proteins are tagged with ubiquitin involves a three step
process. The E1 ubiquitin-activating proteins first establish a form of ubiquitin (Ub)
which is highly reactive.9 After activation, the ubiquitin is forwarded from an E1 to
ubiquitin carriers known as E2 proteins.9 E2 proteins typically exhibit a conserved core
region of 16kDa.10 This region contains cysteine, which is used in the thiol-ester linkage
between the activated ubiquitin and the enzyme.10 The main function of these E2 enzymes
is to serve as ubiquitin couriers for E3 ubiquitin-protein ligases, such as MuRF1. The E3
ubiquitin ligases transfer the activated ubiquitin to a lysine residue on the final protein
substrate, typically forming long ubiquitin chains which are then recognized by the 26S
proteasome. It is likely that it is the E3 ligase which is responsible for the discrimination
and accuracy of the process of ubiquination.11 The resulting ubiquitin-tagged protein
3|P age

complex is then broken down into small peptides by the proteolytic activity of the 26S
proteasome.12 In skeletal muscle, this breakdown of protein may contribute to loss of
muscle mass. MuRF1, which has been classified as an E3 ubiquitin ligase, has been well
characterized as a general marker of skeletal muscle wasting.1

MuRF1 as a Marker of Skeletal Muscle Atrophy
MuRF1 expression has previously been shown to be induced under different
atrophy conditions.1 This work measured changes in mRNA levels over time in
experimental subject mice following atrophy-inducing conditions, including denervation
of the sciatic nerve, immobilization of the hind limbs, and hind-limb suspension.1
Following transcript profiling, Northern blots were used to verify the expression patterns
of potential genes of interest (Figure 2).1 While many genes showed increased expression
under one or two conditions, only two genes showed significant up-regulation under all
three atrophy conditions. These two key genes are Muscle RING (Really Interesting New
Gene) Finger-1 (MuRF1) and Muscle Atrophy F-box (MAFbx).

Image redacted, paper copy available upon request to home
institution.

Figure 2. Northern Blot of MuRF1 and MAFbx expression. MuRF1 and MAFbx gene expression in mice
are found to increase in expression over time following immobilization, denervation, and hind limb
suspension. Numbers represent days post-denervation.1
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Since MuRF1 is quickly and significantly up-regulated following atrophyinducing conditions, it is believed to be a major player in the atrophic process via the
mediation and subsequent proteolytic degradation of target proteins. Indeed, mice that are
deficient in MuRF1 show significant resistance to muscle atrophy following denervation,
immobilization, and hind limb suspension.1 Surprisingly, in the dozen years since their
discovery, very few targets of MuRF1 and MAFbx have been characterized leading to a
reevaluation of the role of these genes in the atrophy cascade. To this end, data from a
microarray comparing gene expression profiles in MuRF1-null and wild-type mice under
neurogenic atrophy conditions was conducted and recently published.6 The results of that
investigation suggest a possible transcriptional regulatory role for MuRF1.6 Therefore, it
was the goal of this research to characterize the mechanism by which MuRF1 might act
as a transcriptional modulator of atrophy-induced gene expression.

Additional Roles of MuRF1in the Muscle Atrophy Cascade
There are aspects of both MuRF1 and MAFbx that suggest these genes may play
additional roles in the atrophy processes. First, these E3 ligases have few known targets
within skeletal muscle, and of the known targets, one is a muscle-specific transcription
factor called MyoD1.13 This muscle-specific transcription factor has been shown to be
targeted for degradation specifically by MAFbx.13 Because this tagging of MyoD1 may
likely cause other downstream changes in gene expression, this finding supports the
possibility that these E3 ligases may play a more global role in gene regulation than
previously thought. Furthermore, MuRF1 has been hypothesized to monoubiquitinate
some target substrates in cardiac muscle.14 For example, it has recently been suggested
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that MuRF1 monoubiquinates the peroxisome proliferator-activated receptor alpha
(PPARα) and regulates its nuclear localization in cardiac muscle.14 In contrast to
polyubiquitination, monoubiquitination is not commonly believed to cause degradation
by the proteasome. Monoubiquitination of proteins more commonly serves to change the
protein’s structure, function, cellular localization, or serves as a signal for the recruitment
and binding of additional transcription factors.15 The nuclear localization of PPARα in
response to modification by MuRF1 in cardiac muscle gives precedence that MuRF1
could act as a potential regulator of protein function beyond its assumed role of simply
targeting proteins for degradation. Therefore, we hypothesized that MuRF1 may serve to
tag proteins for further regulation in skeletal muscle in addition to tagging proteins for
degradation by the proteasome.

Important Structural Characteristics of MuRF1
The first step to better understanding the function and regulation of MuRF1 was
the exploration of the proposed three-dimensional structure of its gene product. The
different functional domains of MuRF1 suggest that this E3 ligase may have distinct
functions in muscle. MuRF1 contains a well-characterized RING domain needed for E3
ligase activity as well as additional domains of interest described below. A RING domain
is a zinc finger with a consensus sequence of C-X2-C-X[9-39]-C-X[1-3]-H-X[2-3]-C-X2-CX[4-48]-C-X2-C, in which C represents a conserved cysteine residue, H represents a
conserved histidine, and X represents any amino acid. The cysteine and histidine residues
are involved in interacting with zinc ions, and RING fingers frequently bind
ubiquitination enzymes as well as target proteins in order to facilitate ubiquitination.16 A

6|P age

sequence alignment of the MuRF1 protein from mouse, rat, and human is shown in
Figure 3.

Figure 3. Alignment of MuRF1 P
Protein. MuRF1 protein sequences from mouse, rat and human were downloaded from
the PubMed database (www.PubMed.org). The proteins were then aligned using sequence alignment tools
(http://www.ncbi.nlm.nih.gov).

The RING domain is predicted to perform the catalytic
tic action of MuRF1 as it
participates in the ubiquitina
ubiquitination processes. The B-box and B-box
box c-terminal
c
(Bbc)
domains are thought to form additional zinc fingers that may play roless in DNA and/or
protein binding. The
he acidic cc-terminus of MuRF1 is of special interest and has no known
function; however acidic protein tails may have possible roles in the cellular location of
proteins, including nuclear translocation
translocation.17, 18
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MuRF1 as a Transcriptional Regulatory Factor in Skeletal Muscle
Microarray data comparing different
differential
ial gene expression profiles in MuRF1-null
and wild-type mice under denervation conditions suggest that MuRF1 may act as a
potential transcriptional regulatory factor in skeletal muscle.6 The MuRF1 knock-out
(KO) mouse was engineered via insertion of a β-galactosidase-encoding
encoding lacZ cassette
within the MuRF1 gene.1 Thus, under control of the endogenous
ndogenous MuRF1 promoter, the
MuRF1 gene product was expressed in the wild
wild-type
type mouse, while the β-galactosidase
gene product was produced in the knockout mouse. This allowed for quantification of the
different gene products (i.e.
i.e. β-galactosidase vs MuRF1) under control of the endogenous
MuRF1 promoter.
MuRF1 gene expression increased in the wild
wild-type mice following denervation;
denerva
however, it decreased back to baseline by 14 days following denervation (Figure 4A). In
contrast, the levels of β-galactosidase
galactosidase increased and remained elevated in the MuRF1-null
MuRF1
animals at 14 days post-denervation
denervation (Figure 4B).
A

B

Figure 4. Microarray data showing MuRF1 and β-galactosidase expression in wild-type
type (WT) and MuRF1-null (KO)
mice. (A) The MuRF1 gene expression rises following denervation but returns to baseline by day 14 in WT mice. (B)
In contrast, β-galactosidase
galactosidase expression remains elevated at 14 days in KO mice.. Whole genome expression analysis
was conducted on gastrocnemius muscle from wild
wild-type (WT) and MuRF1-null
null (KO) mice following 3 days (3D) and
14 days (14D) denervation. Each condition was conducted in triplicate and the expression is the average of three
individual mice. Error bars represent +/
+/- S.E.M of the average expression of the three individual animals from each
6
condition.
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The significance of this data rests in the maintenance of elevated expression of βgalactosidase (β-gal) over time in the MuRF1 KO animals,, as compared to the transient
increase in expression of MuRF1 and the subsequent return to baseline by 14 days postpost
denervation in the wild-type
type mice
mice. Because β-gal (in the KO mice) and MuRF1 (in the
wild-type mice) are under the control of the same regulatory region,, it is reasonable to
hypothesize that MuRF1 may feedback and repress its own transcriptional activity.
activity
Furthermore, MuRF1 also appears to be necessary for repression of MAFbx
expression following denervation. MAFbx gene activity increases fo
following
llowing denervation
but returns to baseline by 14 days post-denervation in wild-type
type mice (Figure 5A).
However, in the MuRF1 KO mice, MAFbx expression increases following denervation
and remains elevated (Figure 5B).

A

B

Figure 5. Microarray data showing MAFbx expression in wild-type (WT) MuRF1-null (KO) mice. (A) MAFbx gene
expression rises following denervation but returns to baseline by day 14 in WT mice. (B) In contrast, MAFbx
expression remains elevated at 14 days in KO mice at 14 days. Whole genome expression analysis was conducted on
gastrocnemius muscle from wild
wild-type (WT) and MuRF1-null
null (KO) mice following 3 days (3D) and 14 days (14D)
denervation. Each condition was conducted in triplicate and the expression is the average of three individual mice.
6
Error bars represent +/- S.E.M of the average expression of the three individual animals from each condition.

In light of the above data, the work described in this thesis explores
explor the potential
transcriptional regulatory actions of MuRF1 in skeletal muscle tissue.. Specifically, this
9|P age

research examines the ability of MuRF1 to negatively transcriptionally regulate itself and
other atrogenes,, including MAFbx. Additionally, because MuRF1 codes for a protein
p
found in skeletal muscle, the potential interaction of MuRF1 with myogenic regulatory
factors (MRFs),, which are also dramatically up
up-regulated
regulated in response to neurogenic
atrophy (i.e. denervation), was also investigated.

Myogenic Regulatory Factor Regulation of MuRF1 and MAFbx Expression
The transcriptional regulation of MuRF1 and MAFbx by myogenic regulatory
factors (MRFs) has been previously analyzed.19 These transcription factors ultimately act
in concert with co-activators
activators or co
co-repressors to mediate transcription of muscle-specific
genes.20

Figure 6. MAFbx Promoter Alignment.
lignment. Promoter sequences from mouse, rat, and human MAFbx genes (5000 base
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database
(www.ensembl.org) and aligned using the ClustalW algorithm. Identica
Identicall sequences for the indicated regions are
highlighted in black. Approximate positions of potential MRF transcription factor binding sites are circled in the
alignment : O class, or FoxO, Forkhead binding site (G/A)TAAA(T/C)AA ((Ovals);
); C/EBP TT(G/T)NGNAA
(Diamonds);
); Muscle specific E box CANGTG (MyoD, etc.) ((Large circle)
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Notably, the proximal promoters of both MuRF1 and MAFbx contain E-box
E
consensus
sequences (5'-CANNTG--3')
3') which are known sites of MRF binding (Figure 6 and Figure
7).21 The E-boxes
boxes in both the MuRF1 and MAFbx proximal promoter
promoterss have previously
been shown to interact with myogenic regulatory factors,, including MyoD1 and
myogenin.22 Furthermore, MyoD1 and myogenin levels increase sharply in response to
neurogenic atrophy of muscle and lead to the induction of MuRF1 and MAFbx
expression (Figure 8).6

Figure 7. MuRF1 Promoter Alignment. Promoter sequences from mou
mouse,
se, rat, and human MuRF1 genes (5000 base
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database
(www.ensembl.org) and aligned using the ClustalW algorithm. Identical sequences for the indicated
indicate regions are
highlighted in black. Approximate positions of potential transcription factor binding sites are indicated in the
schematics and highlighted in the alignments
alignments: FoxO, (G/A)TAAA(T/C)AA Ovals);
); C/EBP TT(G/T)NGNAA
(Hexagons);
); Muscle specific E box CANGTG (MyoD1, etc.) (Large Circles)
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A

B

Figure 8. Microarray data showing MyoD1 and myogenin expression profiles under atrophy conditions in wild-type
wild
(WT) and MuRF1-null
null (KO) mice. (A) MyoD1 and (B) myogenin expression levels following 3 days (3D) and 14 days
(14D) of denervation. Whole genome expression analysis was conducted on gastrocnemius muscle from wild-type
wild
(WT) and MuRF1-null
null (KO) mice following 3 days (3D) and 14 days (14D) of denervation. Each condition was
conducted in triplicate and the expression is the average of three individual mice. Error bars represent +/+/ S.E.M of the
6
average expression of the three individual animals from each condition.

MyoD1 and myogenin are basic helix-loop-helix (bHLH) transcription factors.
factors 22
Basic helix-loop-helix
helix transcription factors are characterized by a protein motif consisting
of two α-helices
helices connected by a loop. DNA binding is facilitated by tthe
he basicity of the
amino acid residues of one of the loops.23 Myogenic regulatory factors such as MyoD1
and myogenin bind to the 5'
5'-CANNTG-3' E-box
box consensus sequence, and often play roles
in myogenic differentiation
ation and proliferation.24 For example, MyoD1 is an early marker
of myogenic commitment to the skeletal muscle lineage and is known to halt proliferation
of muscle cells by increasing transcription of p21, effectively removing cells from the
cell cycle.25 Interestingly, differentiated C2C12 mouse myoblast cells undergoing
under
MyoD1
knockdown have been shown to ddedifferentiate and re-enter
enter the cell cycle as proliferating
myoblasts.26 In contrast to MyoD
MyoD1,, myogenin is known to be necessary for proper
development of skeletal muscle.27 Mice without functional myogenin are unable to
produce mature functional
unctional muscle fibers.28 Myogenin
yogenin has previously been shown to bind
12 | P a g e

to the MuRF1 and MAFbx promoters and mice without myogenin lose the ability to upregulate MuRF1 and MAFbx following denervation.22
Current dogma states that MuRF1 and MAFbx regulate skeletal muscle dynamics
by targeting proteins for degradation, but increasing evidence, including data presented in
this thesis, suggests that MuRF1 may also function as a muscle-specific transcription
factor. In light of the information described herein, the regulation of MuRF1 and MAFbx,
as well as the role of MuRF1 as a transcriptional modulator of atrogene regulation was
explored. The data in this thesis supports the hypothesis that MuRF1 may act as a
transcriptional regulator of muscle-specific gene expression.
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Chapter 2: Transcriptional Repression of Atrogenes by MuRF1 and Myogenic Regulatory
Factors

Introduction
Skeletal muscle is highly organized, and is the most abundant tissue by mass
found in the human body. Skeletal muscle tissue is dynamic and is able to readjust its size
not only as a response to nutritional status, but also as a response to many other cues
including stress, mechanical load, neural activity, hormones and growth factors. While
the main function of skeletal muscle is involved in movement and force generation,
skeletal muscle also plays a major role in global metabolism and the maintenance of
energetic homeostasis. For example, during periods of low nutrition, skeletal muscle
tissue is capable of releasing amino acids that are used in the liver to raise glucose levels
via gluconeogenesis.29 Skeletal muscle is necessary for normal metabolic processes, and
recent evidence suggests that skeletal muscle may communicate with the rest of the body
in order to maintain normal metabolic functions of other tissues and organs.30
Skeletal muscle atrophy, or loss of muscle mass, is characterized by a reduction in
protein content and fiber diameter, and a concomitant decrease in force production. The
E3-ubiquitin ligase, MuRF1 is hypothesized to be a major regulator of the atrophy
process. MuRF1 is thought to function in the atrophy cascade since it is expressed
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predominantly in skeletal muscle, is up-regulated after varied atrophic stressors, and
deletion of the MuRF1 gene leads to resistance of muscle loss following denervation in
mice.1,

22, 31

MuRF1 is well characterized as a participant in the proteolytic pathways;

however, there is evidence that it may play additional roles in muscle plasticity. The
recently discovered nuclear localization of peroxisome proliferator activated receptor
alpha (PPARα) via monoubiquitination by MuRF1 in cardiac muscle provides a
precedence that the ubiquitin ligase activity of MuRF1 may serve to tag proteins for
further regulation in skeletal muscle in addition to just simply tagging them for
degradation by the proteasome.14
MuRF1 and MAFbx are both up-regulated under numerous conditions of muscle
atrophy, but these genes have few known targets within skeletal muscle.1 Of the known
targets, at least one of them is a muscle-specific transcription factor called MyoD1, which
has been shown to be targeted for degradation by MAFbx.13 Because this may likely
cause other downstream changes in gene expression, this supports the possibility that
these atrophy-induced E3 ligases may also play a role in gene regulation under atrophic
conditions.
Microarray data comparing wild-type and MuRF1-null mice under denervation
conditions suggest that MuRF1 may be a potential transcriptional regulatory factor in
skeletal muscle.6 MuRF1 gene expression increases in wild-type mice following
denervation; however, it decreases back to baseline expression levels by 14 days postdenervation. When the MuRF1 gene is disrupted via insertion of a LacZ cassette, the
MuRF1 promoter remains active with no subsequent decline to baseline,6 suggesting a
possible negative-feedback loop in which the MuRF1gene product causes repression of
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its own promoter. In addition, MAFbx gene activity also increases following denervation
and returns to baseline expression levels by 14 days in wild-type mice but remains
elevated in the MuRF1 KO mice at 14 days post-denervation.6 Therefore, it is reasonable
to propose that MuRF1 expression may lead to the transcriptional regulation of other
atrogenes, though the mechanism of this control remains unclear.
There are distinct functional domains of the MuRF1 gene product which might be
implicated in the potential role of MuRF1 as a transcriptional regulatory factor. MuRF1
contains a well-characterized RING (really interesting new gene) domain needed for E3
ligase activity. RING fingers frequently bind ubiquitination enzymes as well as target
proteins, and are thus predicted to perform the catalytic action of E3-ubiquitin ligase
enzymes.32 The B-box and B-box c-terminal (Bbc) domains of MuRF1 are thought to be
zinc fingers that may play a role in DNA and/or protein binding.33 The acidic c-terminus
of MuRF1 is of special interest and has no known function; however acidic protein tails
may have a role in cellular localization, including nuclear translocation.17, 18 Mutations
were introduced during our work to inactivate the RING domain or delete the c-terminal
domain of MuRF1 to better explore the potential roles of these domains in transcriptional
regulation by MuRF1.
The work presented in this thesis examines the potential transcriptional
regulatory actions of MuRF1 in skeletal muscle atrophy. Specifically, the ability of
MuRF1 to negatively transcriptionally regulate itself and other atrogenes, including
MAFbx, was explored using reporter assays to measure MuRF1 and MAFbx expression
under various conditions, including in response to overexpression of MuRF1.
Additionally, because MuRF1 codes for a protein found in skeletal muscle, the potential
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interaction of MuRF1 with myogenic regulatory factors (MRFs) was also explored.
Finally, in order to determine if MuRF1 catalytic activity was necessary for the ability of
MuRF1 to modulate transcription, mutations were introduced in order to inactivate the
RING domain or delete the carboxyl-terminal domain. The data presented below provides
an analysis of the role of MuRF1 as a transcriptional regulator of atrogenes. This thesis
proposes a new function for MuRF1 in the skeletal muscle atrophy process beyond its
classical role as a post-translational ubiquitinator of target proteins.

Materials and Methods

Cell Culture
C2C12 mouse myoblast cells were obtained from a cryostored stock (American
Type Culture Collection, Manassas, VA). The cells were thawed, and subsequently
grown in a 10 cm cell culture dish in 10 mL of proliferation media (DMEM
supplemented with 10% FBS, Pen/Strep, nonessential amino acids, and gentamycin) at
37°C in a 6% CO2 humidified chamber.

Transfections and SEAP Reporter Assays
C2C12 cells were plated at a density of 50,000 cells/well into 12-well plates and
cultured until an approximate confluency of 70-90% was reached. Prior to transfection,
media was aspirated from cells, and 1 mL of fresh proliferation media was added. A total
of 1 µg of DNA/well was transiently transfected into each well of the 12-well plates. The
transfected DNA cocktail consisted of 250 ng/well of reporter construct, 125 ng/well of
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pCMV-β-Galactosidase and 125 ng/well of expression plasmids (i.e., pcDNA3.1-MuRF1,
pcDNA3.1-MuRF1-RING-mut,

pcDNA3.1-MuRF1-c-term-mut,

pcDNA3.1-MyoD1,

and/or pcDNA3.1-myogenin), and pBluescript as filler to bring to 1 ug/well total DNA.
The DNA mixtures were then added to TransIT-LT1 Transfection Reagent (MirusBio,
Madison, WI) diluted in unsupplemented DMEM according to the manufacturers
protocol.

The DNA/LT-1 solutions were mixed gently, and incubated at room

temperature for 30 min. Following the 30 minute incubation, 75 µL of DNA/LT-1
mixture for each reaction condition was added to each well of C2C12 cells in a 12-well
plate. The C2C12 cells were incubated at 37°C and 6% CO2 for 24 hours, and then 1 mL
of fresh differentiation media (DMEM with 2% FBS, Pen/Strep, nonessential amino acids
and gentamycin) was added to each well to induce myoblast differentiation. Levels of
secreted alkaline phosphatase (SEAP) were measured at 24, 48, and 72 hours post-media
change using a commercial protocol from Clontech Laboratories according to the
manufacturer’s instructions (Mountain View, CA.). The C2C12 myotubes were lysed at
the conclusion of each experiment, and SEAP numbers were normalized to βgalactosidase activity to correct for variations in transfection efficiency. Each condition
was done in triplicate and error reflects +/- standard deviation.

Promoter Cloning of MuRF1 and MAFbx
Cloning of the pSEAP-MuRF1-Pro500, pSEAP-MuRF1-Pro1000, pSEAPMuRF1-Pro2000, pSEAP-MuRF1-Pro5000, pSEAP-MAFbx-Pro500, pSEAP-MAFbxPro1000, pSEAP-MAFbx-Pro2000, and pSEAP-MAFbx-Pro5000 plasmids has been
previously described. 34 The 500 bp, 1000 bp, 2000 bp, and 5000 bp promoter fragments
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were amplified by PCR using BAC clones purchased from CHORI (Oakland, CA). The
resulting PCR product was cloned into the SEAP2-Basic reporter vector (Clontech
Laboratories).

MuRF1 cDNA Cloning
RNA was extracted from homogenized C2C12 mouse muscle cells using RNeasy
columns per the manufacturer’s protocol (Qiagen, Valencia, CA). Mouse cDNA was
reverse-transcribed from the mouse mRNA using the following conditions: oligo (dT)
primers (500 µg/ml) and dNTP mixture (2.5 mM) were combined with mouse mRNA
(1 ng) with nuclease-free sterile water. The mixture was incubated at 65°C for 5 minutes
and then incubated on ice for 1 minute. The mixture was briefly centrifuged and FirstStrand Buffer (Invitrogen Corporation, Carlsbad, CA), DTT (0.1 M), and Ribonuclease
Inhibitor were added per manufacturer’s instructions. The mixture was briefly mixed and
incubated at 37°C for 2 minutes, followed by the addition of Moloney Murine Leukemia
Virus (M-MLV) Reverse Transcriptase (Invitrogen Corporation). The reaction was then
incubated at 37°C for 50 minutes followed by heat inactivation at 70°C for 15 min. The
MuRF1 cDNA was amplified via PCR using the C2C12 and gene specific primers, cloned
into the EcoRI/XbaI sites of pcDNA3 and sequenced to confirm the identity of the
cDNA.
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Generation of MuRF1 Mutants
The MuRF1 DNA and protein sequences were downloaded from the PubMed
database (www.PubMed.org). The MuRF1 protein sequences for rat, mouse and human
were then aligned using sequence alignment tools (http://www.ncbi.nlm.nih.gov). These
alignments were then used to identify conserved amino acids for site-directed
mutagenesis. Site-directed mutagenesis reactions were performed as instructed in the
manufacturer's protocol (Stratagene, La Jolla, California). Site-directed mutagenesis
primers were designed and used to introduce mutations in the RING domain or the acidic
c-terminal tail region of the MuRF1 gene. The c-terminal MuRF1 mutant was created
using the following primer sequences:

FWD: 3’-CTTTGGGACAGATTAGTTAGGAGGAGGAGGAGGAG-5’,
REV: 3’-CTCCTCCTCCTCCTCCTACTAATCTGTCCCAAAG-5’. The MuRF1 RING
mutant was generated using the following primer sequences:
FWD: 3’CCAACACCAACCTCAGCCGGAAGAGTGCCAACGACATC-5’ and
REV: 3’-GATGTCGTTGGCACTCTTCCGGCTGAGGTTGTGTTGG-5’. The resulting
clones were sequenced to confirm introduction of the correct mutation.

Generation of E-box Mutations in the MuRF1 Promoter
The two E-boxes identified in the MuRF1 proximal promoter were mutated via
site-directed mutagenesis. Site-directed mutagenesis was performed on the MuRF1Pro500-SEAP reporter plasmid as instructed in the manufacturer's protocol (Stratagene).
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The primer sequences used to mutate the E-box at position -156 in the MuRF1 promoter
were:
FWD-5’-GGCCCTCTCAGATCCAGGCAGGGATG-3’ and
REV-3’-GCTCATCCCTGCCTGGGACTGAGAGGGCC-5’.
The primer sequences used to mutate the E-box at position -57 in the MuRF1 promoter
were FWD-5’-CCTCCTGGGGCTCCTGGGACAGAGGTGCAGC-5’ and
REV-3’- GCTGCACCTCTGTCCCAGGAGCCCCAGGAGG-3’.
The resulting DNA was sequenced to confirm introduction of the correct mutation.

Construction of a Concatemerized 4X E-box Reporter
Four discrete E-boxes were cloned upstream of a minimal SV40 promoter fused
to the SEAP reporter gene (Figure 9). Oligonucleotides with sequences of FWD-5’CGCGCCTGCATGTGATAT-3’ and REV-5’-CGCGAGATCACATGCAGG-3’ were
end-phosphorylated using T4 Polynucleotide Kinase and then annealed by mixing and
heating to 95°C for two minutes and slowly cooling to 25°C for 45 minutes in a
thermocycler. The annealed oligonucleotides were then ligated into the MluI site in front
the SV40 minimal promoter of linearized pSEAP2-Promoter plasmid (Clontech) and
sequenced to confirm insertion and orientation.
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Western Blotting
C2C12 cells were transfected with either pcDNA-MuRF1 or pcDNA-MuRF1RING mutant expression plasmids. The cells were harvested at 72 hours post-transfection
and lysed using 500 µL of Universal Lysis Buffer (ULB) (50 mM Tris, 150 mM NaCl,
50 mM NaF, 0.5% Igepal, 1 mM PMSF, 1mM DTT, 10mM β-glycerophosphate , 2 mM
Sodium Molybdate and a protease inhibitor cocktail) . The cells were then incubated on
ice for 30 minutes and centrifuged at 4°C for 5 minutes at 18,000 × g. The supernatant
was then transferred to new 1.5mL Eppendorf tubes and stored at -80˚C. Protein
concentrations were determined using a modified Bradford protein assay method
according to the manufacturer’s protocol (BioRad, Hercules, CA). Total protein (200µg)
was separated on an SDS-PAGE gel, and then transferred overnight to a polyvinylidene
difluoride (PVDF) membrane. The membrane was blocked for one hour with a blocking
solution of 5% milk + 0.05% Tween in Tris Buffered Saline (TTBS). The blocked
membrane was then probed by a protein-specific primary antibody. Commercially
available primary antibodies for MyoD1 (M-318, rabbit, Santa Cruz Biotechnology, Inc.,)
and myogenin (F5D, mouse, Santa Cruz Biotechnology, Inc.,) were incubated with the
membrane at a concentration of 1:500 for 1 hr with shaking. Following four washes with
TTBS, the membrane was incubated with an appropriate secondary antibody at a 1:5000
concentration for 1 hour and then washed in TTBS. Signal development closely followed
manufacturer’s instructions for the Pierce ECL Western Blotting kit and imaged using the
Typhoon Imager (Thermoscientific, Rockford, IL.).
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Results

Transcriptional Repression of MAFbx Expression by MuRF1
The ability of MuRF1 to regulate the expression of MAFbx was first tested using
a series of MAFbx promoter constructs, and the results revealed that the MAFbx reporter
constucts are repressed by MuRF1 ectopic expression. A reporter plasmid containing a
500 bp MAFbx proximal promoter fragment fused to SEAP (MAFbx-Pro500) was
cotransfected into C2C12 cells with or without a MuRF1 expression plasmid. As shown in
Figure 9, the MAFbx 500 bp promoter shows a significant decrease in activity in cells
overexpressing MuRF1.
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Figure 9. MAFbx-Pro500 reporter shows transcriptional repression in response to overexpression of MuRF1. C2C12
myoblasts were transfected with a reporter construct consisting of the MAFbx-500bp promoter fragment fused to the
SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and an expression plasmid for MuRF1. The myoblasts
were maintained in standard differentiating culture media. Samples of media were taken at 24 hr intervals and
measured for SEAP activity. The samples were normalized with β-galactosidase activity to correct for variation in
transfection efficiency. Each condition was done in triplicate and error bars represent standard deviation (-/+ S.D.) of
the mean.
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Cooperative Regulation of MAFbx Expression by MuRF1 and Myogenic Regulatory
Factors
MuRF1 negatively regulates the transcriptional activity of MAFbx as shown in
Figure 9 above. Since the MAFbx proximal promoter contains a functional E-box and has
previously been shown to be up-regulated by the myogenic regulatory factors MyoD1
and myogenin,22 we next tested if MuRF1 overexpression might modulate MRF
transcriptional regulation of MAFbx. These experiments show that MyoD1 causes
activation of the MAFbx-Pro500 reporter. However, co-overexpression with MuRF1 not
only reversed MyoD1 activation, but also caused a cooperative repression of the MAFbxPro500 reporter (Figure 10A). In addition, the MuRF1/MRF combinatorial effect was
also observed when the MAFbx-Pro500 reporter was transfected into cells along with
MuRF1 and myogenin expression plasmids. Co-overexpression of MuRF1 with
myogenin also resulted in significant repression of the MAFbx-Pro500 reporter activity
(Figure 10B).
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Figure 10. MuRF1 and MRFs Cooperatively Regulate MAFbx Reporter Activity. The MAFbx-Pro500 shows
transcriptional repression in response to co-overexpression of MuRF1 and (A) MyoD1 and (B) myogenin. C2C12
myoblasts were transfected with a reporter construct consisting of the MAFbx-500bp promoter cloned into the SEAP2Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for MuRF1 alone or in combination with
MyoD1 or myogenin. The myoblasts were maintained in standard differentiating culture media. Samples of media were
taken at 24 hr intervals and measured for SEAP activity. The samples were normalized to β-galactosidase activity to
correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars represent
standard deviation (-/+ S.D.) of the mean.

25 | P a g e

The MuRF1/MRF repressive effect was also observed when larger regions (i.e.
1000 bp, 2000 bp and 5000 bp fragments) of the MAFbx proximal promoter were
evaluated (Figure 11 and Figure 12). For all fragment sizes of the MAFbx promoter that
were evaluated, overexpression of MuRF1 caused significant transcriptional repression.
Furthermore, overexpression of MyoD1 or myogenin caused transcriptional activation of
the 1000 bp MAFbx promoter but caused repression of the 2000 bp and 5000 bp MAFbx
reporter constructs. In a pattern similar to that seen in the MAFbx 500 bp promoter,
cooperative repression of the MAFbx 1000, 2000 and 5000 bp promoter fragments by
MuRF1 in combination with MyoD1 (Figure 11) or myogenin (Figure 12) was observed.
In all cases, the repressive trend on the MAFbx reporter constructs by the cooverexpression of MuRF1/MyoD1 or MuRF1/myogenin was significantly greater than
that caused by any factor individually.
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Figure 11. MuRF1and MyoD1 cooperatively regulate larger MAFbx promoter fragments. The (A) 1000 bp, (B) 2000
bp, and (C) 5000 bp promoters of MAFbx show cooperative repression when MyoD1 is expressed in combination with
MuRF1. C2C12 myoblasts were transfected with a reporter construct consisting of either the MAFbx 1000 bp, 2000 bp,
or 5000bp promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression
plasmids for MyoD1 and/or MuRF1. The myoblasts were maintained in standard culture media. Samples of media were
taken at 72 hrs and measured for SEAP activity. The samples were normalized to β-galactosidase activity to correct for
variation in transfection efficiency. Each condition was done in triplicate and the error bars represent standard deviation
(-/+ S.D.) of the mean.
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Figure 12. MuRF1 and myogenin cooperatively regulate larger MAFbx promoter fragments. The (A) 1000 bp, (B)
2000 bp, and (C) 5000 bp promoters of MAFbx show cooperative repression when myogenin is expressed in
combination with MuRF1. C2C12 myoblasts were transfected with a reporter construct consisting of either the MAFbx
1000 bp, 2000 bp, or 5000bp promoter clone into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and
expression plasmids for myogenin and/or MuRF1. The myoblasts were maintained in standard culture media. Samples
of media were taken at 72 hrs and measured for SEAP activity. The samples were normalized to β-galactosidase
activity to correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars
represent standard deviation (-/+ S.D.) of the mean.
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Negative Transcriptional Regulation of MuRF1 Reporter Activity by MuRF1
Previous results suggest that MuRF1 may participate in its own transcriptional
regulation.6 Therefore, we tested the effects of ectopic expression of MuRF1 on MuRF1
reporter constructs in C2C12 cells and observed transcriptional repression of a 500 bp
promoter construct (Figure 13).
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Figure 13. MuRF1 transcriptional regulation of MuRF1 reporter activity. The MuRF1-Pro500 reporter construct shows
transcriptional repression in response to overexpression of MuRF1. C2C12 myoblasts were transfected with a reporter
construct consisting of the MuRF1 500bp promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression
plasmid, and an expression plasmid for MuRF1. The myoblasts were maintained in standard differentiating culture
media. Samples of media were taken at 24 hr intervals and measured for SEAP activity. The samples were normalized
to β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done in triplicate and
the error bars represent standard deviation (-/+ S.D.) of the mean.

The MuRF1 proximal promoter has two functional E-boxes that have previously
been shown to be necessary for proper MuRF1 expression, and have been shown to bind
MyoD1 and myogenin.19, 22 Therefore, we tested the ability of MyoD1 and myogenin to
regulate MuRF1 reporter activity in conjunction with MuRF1 ectopic expression. The
MuRF1 500 bp promoter showed significant activation by both myogenin and MyoD1
(Figure 14), with overexpression of myogenin causing a 10-fold increase in MuRF1
29 | P a g e

promoter activity, while MyoD1 overexpression led to a 50-fold increase in MuRF1
promoter activity. Furthermore, co-overexpression of MuRF1 and MyoD1 reduced
MyoD1-induced MuRF1 promoter activity from 50-fold induction to approximately 10fold induction (Figure 14A), while this MuRF1 reporter showed complete loss of
activation in response to ectopic expression of MuRF1 in combination with myogenin
overexpression (Figure 14B).
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Figure 14. MuRF1 and MRFs cooperatively regulate MuRF1 reporter activity. The MuRF1-Pro500 reporter shows
transcriptional repression in response to co-overexpression of MuRF1 and (A) MyoD1 or (B) myogenin. C2C12
myoblasts were transfected with a reporter construct consisting of the MuRF1-500bp promoter cloned into the SEAP2Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for MuRF1 alone or in combination with
myogenin or MyoD1. The myoblasts were maintained in standard differentiating culture media. Samples of media were
taken at 24 hr intervals and measured for SEAP activity. The samples were normalized to β-galactosidase activity to
correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars represent
standard deviation (-/+ S.D.) of the mean.
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The MuRF1/MRF combinatorial repressive effect was also observed when larger
regions (i.e. 1000 bp, 2000 bp and 5000 bp fragments) of the MuRF1 proximal promoter
were evaluated. The effects of MyoD1 and myogenin either alone or in combination with
MuRF1 on the activity of the 1000 bp, 2000 bp, and 5000 bp promoter regions of MuRF1
were tested, and while the larger sizes of the MuRF1 promoter showed increased general
expression, they showed identical patterns of regulation compared to the 500 bp
promoter. In each case, the MuRF1 promoter fragments showed induction by either
MyoD1 or myogenin alone (Figure 15 and Figure 16, respectively), but this activation
was greatly reduced or completely abolished when MyoD1 or myogenin was expressed in
combination with MuRF1.
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Figure 15. MuRF1 and MyoD1 cooperatively regulate larger MuRF1 promoter fragments. The (A) 1000, (B) 2000, and
(C) 5000 bp promoters of MuRF1 show marked induction by MyoD1 in C2C12 cells, which is largely abolished when
MyoD1 is overexpressed in combination with MuRF1 C2C12 myoblasts were transfected with a reporter construct
consisting of either the MuRF1 1000, 2000, or 5000bp promoter cloned into the SEAP2-Basic plasmid, a βgalactosidase expression plasmid, and expression plasmids for MyoD1 and/or MuRF1. The myoblasts were maintained
in standard culture media. Samples of media were taken at 72 hrs post-media change and measured for SEAP activity.
The samples were normalized to β-galactosidase activity to correct for variation in transfection efficiency. Samples
were done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean.
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Figure 16. MuRF1 and myogenin cooperatively regulate larger MuRF1 promoter fragments. The (A) 1000, (B) 2000,
and (C) 5000 bp promoters of MuRF1 show marked induction by myogenin in C2C12 cells, which is completely
abolished when myogenin is overexpressed in combination with MuRF1 C2C12 myoblasts were transfected with a
reporter construct consisting of either the MuRF1 1000, 2000, or 5000 bp promoter cloned into the SEAP2-Basic
plasmid, a β-galactosidase expression plasmid, and expression plasmids for myogenin and/or MuRF1. The myoblasts
were maintained in standard culture media. Samples of media were taken at 72 hrs post-media change and measured for
SEAP activity. The samples were normalized to β-galactosidase activity to correct for variation in transfection
efficiency. Samples were done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean.
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E-box Sequence is Sufficient for MuRF1/MRF Cooperative Transcriptional Repression
To furtherr characterize the role of the E
E-boxes
boxes found in the MuRF1 500 bp
promoter, a series of four concatemerized E
E-boxes
boxes corresponding to the E-box
E
sequence
at position -156
156 in the MuRF1 regulatory region were cloned in front of a minimal SV40
promoter that contains
ains no enhancers ((Figure 17). Co-overexpression
overexpression of MuRF1 with
either MyoD1 (Figure 18A) or myogenin (Figure 18B) caused a significant repression of
the 4x-Ebox-SEAP
SEAP reporter.

Figure 17. An illustration showing the reporter construct including the orientation of the concatemerization
concatemeriz
of 4
MuRF1 E-boxes
boxes cloned upstream of the SV40 Early Promoter and fused to the pSEAP2-Promoter
Promoter plasmid. The
directions of the arrows represent the 5’
5’ 3’ orientation of the E-boxes.
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Figure 18. The concatemerized 4x-Ebox-SEAP reporter exhibits cooperative repression by MuRF1 and (A) MyoD1 or
(B) myogenin. C2C12 myoblasts were transfected with a reporter construct consisting of the concatemerized 4X-Ebox
construct cloned into the SEAP2-Promoter plasmid, a β-galactosidase expression plasmid, and expression plasmids for
MyoD1, myogenin, and/or MuRF1. The myoblasts were maintained in standard culture media. Samples of media were
taken at 24 hr intervals and measured for SEAP activity. The samples were normalized to β-galactosidase activity to
correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars represent
standard deviation (-/+ S.D.) of the mean.
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MuRF1 Catalytic Activity is Necessary for MuRF1-mediated Reversal of MRF-induced
Reporter Gene Activity
Overexpression of MuRF1 has consistently resulted in little to no repression of
the transcriptional activity of the 4x-Ebox-SEAP reporter, but consistently represses this
construct when co-overexpressed with MyoD1 or myogenin (Figure 18). However, the
MuRF1/MyoD1 cooperative repression of the 4X-Ebox-SEAP reporter is largely
abrogated when MyoD1 is co-overexpressed with a MuRF1-RING-mutant (Figure 19A).
In addition, overexpression of myogenin alone caused a decrease in transcriptional
activity of the 4X-Ebox-SEAP reporter construct, while co-overexpression of myogenin
with MuRF1 resulted in a dramatic cooperative repression of the reporter (Figure 19B).
Furthermore, the overexpression of myogenin in combination with the MuRF1-RINGmutant caused no repression of the 4X-Ebox-SEAP reporter (Figure 19B).
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Figure 19. MuRF1 and MRF cooperative repression of the 4X-Ebox-SEAP reporter is abrogated when (A) MyoD1 or
(B) myogenin is co-overexpressed with the MuRF1-RING-mutant. C2C12 myoblasts were transfected with a reporter
construct consisting of a concatemerized 4X-E-box cloned into the SEAP2-Promoter plasmid, a β-galactosidase
expression plasmid, and expression plasmids for MuRF1, MuRF1-RING-mutant, MyoD1 and/or Myogenin. The
myoblasts were maintained in standard culture media. Samples of media were taken at 72 hrs post-media change and
measured for SEAP activity. The samples were normalized to β-galactosidase activity to correct for variation in
transfection efficiency. Each condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.)
of the mean.
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In order to determine if MuRF1 catalytic activity is also required for cooperative
repression of MuRF1 reporter activity, cells were transfected with the MuRF1-Pro500
reporter construct and MyoD1 along with MuRF1 or the MuRF1-RING mutant.
Overexpression of MyoD1 again caused induction of the promoter construct, which was
partially abrogated by co-overexpression with MuRF1. This abrogation of activation was
not observed when MyoD1 was co-overexpressed with the MuRF1-RING-mutant (Figure
20A). Furthermore, overexpression of myogenin alone caused a significant increase in
the transcriptional activity of the MuRF1-Pro500 construct, which was completely
reversed when myogenin was co-overexpressed in combination with MuRF1. In contrast,
overexpression of myogenin in combination with the MuRF1-RING-mutant actually
caused an increase in reporter transcriptional activity (Figure 20B).
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Figure 20. MuRF1 and MRF cooperative repression of the MuRF1-Pro500 reporter is abrogated when (A) MyoD1 or
(B) myogenin is co-overexpressed with the MuRF1-RING-mutant. C2C12 myoblasts were transfected with a reporter
construct consisting of MuRF1 500 bp promoter fragement cloned into the SEAP2-Basic plasmid, a β-galactosidase
expression plasmid, and expression plasmids for MuRF1, MuRF1-RING-mutant, MyoD1 and/or Myogenin. The
myoblasts were maintained in standard culture media. Samples of media were taken at 72 hrs post-media change and
measured for SEAP activity. The samples were normalized to β-galactosidase activity to correct for variation in
transfection efficiency. Each condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.)
of the mean.
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The MuRF1 Acidic Carboxyl-Terminal Tail is Not Required for MuRF1-mediated
Reversal of MRF-induced Reporter Gene Activity
Truncation of the acidic c-terminus of the MuRF1 protein did not significantly
alter the cooperative repression of the 4X-Ebox-SEAP reporter by MuRF1 and MyoD1.
As shown previously, the transcriptional activity of this reporter is repressed in response
to ectopic expression of MyoD1 alone, while this repression is further increased when
MyoD1 was co-overexpressed in combination with MuRF1 (Figure 21). Furthermore,
overexpression of MyoD1 in combination with the MuRF1-c-terminal mutant was

RLU (+/- SD)

indistinguishable from co-overexpression of MyoD1 with full-length MuRF1 (Figure 21).
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Figure 21. The MuRF1-c-terminal mutant in combination with MyoD1 cooperatively represses the 4X-Ebox-SEAP
reporter. C2C12 myoblasts were transfected with a reporter construct consisting of the concatemerized 4X-E-boxes
cloned into the SEAP2-Promoter plasmid, a β-galactosidase expression plasmid, and expression plasmids for MuRF1,
MuRF1-c-terminal-mutant, and/or MyoD1. The myoblasts were maintained in standard culture media. Samples of
media were taken at 72 hr and measured for SEAP activity. The samples were normalized to β-galactosidase to correct
for variation in transfection efficiency. Samples were done in triplicate and the error bars represent standard deviation
(-/+ S.D.) of the mean.

In order to further determine if the carboxyl-terminal region of MuRF1 is required
for cooperative repression of the MuRF1 expression, cells were transfected with the
MuRF1-Pro500 reporter construct and MyoD1 along with MuRF1 or the MuRF1-C-term
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mutant. As shown previously, overexpression of MyoD1 caused a significant increase in
transcriptional reporter activity, which was completely abolished when MyoD1 was cooverexpressed in combination with MuRF1. Furthermore, overexpression of the Cterminal MuRF1 mutant alone showed no appreciable difference compared to the effect
of full-length MuRF1 on the transcriptional activity on the MuRF1-Pro500 reporter
construct, while co-overexpression of the MuRF1 c-terminal mutant with MyoD1 also
showed no significant differences on the MuRF1-Pro500 reporter when compared to
MuRF1/MyoD1 co-overexpression (Figure 22).
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Figure 22. The MuRF1-c-terminal mutant in combination with MyoD1 cooperatively represses the MuRF1-Pro500
reporter. C2C12 myoblasts were transfected with a reporter construct consisting of the MuRF1 500 bp promoter
fragment cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for
MuRF1, MuRF1-c-terminal-mutant, and/or MyoD1. The myoblasts were maintained in standard culture media.
Samples of media were taken at 72 hr and measured for SEAP activity. The samples were normalized to βgalactosidase to correct for variation in transfection efficiency. Samples were done in triplicate and the error bars
represent standard deviation (-/+ S.D.) of the mean.
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Ectopic Expression of MuRF1 Does Not Alter Endogenous Myogenin Protein Levels
Myogenin protein levels were unchanged in C2C12 cells overexpressing either
MuRF1 or the MuRF1-RING mutant. This data suggests that the mechanism by which
MuRF1 modulates MRF activity is not simply due to destabilizing these myogenic
regulatory factors (Figure 23).
MuRF1-RINGMuRF1
100

200

Mutant

100

200

Figure 23. Similar levels of myogenin protein observed in C2C12 cells over-expressing MuRF1 and in C2C12 cells overexpressing the MuRF1-RING-mutant. C2C12 myoblast cells were transfected with an expression plasmid containing
either MuRF1, or the MuRF1-RING-mutant. The myoblasts were maintained in standard culture media and harvested
at 72 hours. Western blotting was performed on 100µg and 200µg of total protein using antibodies against myogenin.

Discussion
MuRF1 expression increases in response to an array of atrophy-inducing
conditions;1 however, the mechanism of the transcriptional regulation of this gene is still
not completely understood. Furthermore, the results from this study suggest that MuRF1
may also play a role in the transcriptional regulation of a subset of atrogenes, including
itself. MuRF1 has been shown through this research to be an inhibitive transcriptional
regulator of the MAFbx and MuRF1 gene. These results are consistent with recent
microarray data in which MuRF1-null animals showed differential gene expression
compared to wild-type (WT) littermates.6 MuRF1-null animals exhibited continued
elevation of MuRF1 (evidenced by increased β-gal expression in the MuRF1-null mice)
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and MAFbx expression following denervation, while the expression of these genes
returned to baseline in the WT mice following denervation. MuRF1 has long been
described as a marker for muscle atrophy, given that the expression of MuRF1 increases
in response to numerous atrophic stimuli1; however, the present study expands the role of
MuRF1 to include that of a regulator of atrophy-induced gene expression.
Furthermore, this thesis provides insight into the mechanisms by which MuRF1
inhibits atrophy-induced gene expression. Specifically, we show that MuRF1 acts, at least
in part, via direct and/or indirect modulation of the MyoD-family of myogenic regulatory
factors, including MyoD1 and myogenin. MyoD1 and myogenin are basic helix-loophelix proteins that have been shown to bind E-boxes in the promoters of muscle specificgenes.22 In addition, we have confirmed transcriptional activation of MuRF1 and MAFbx
by MyoD1 and myogenin; however, we demonstrate for the first time here that MuRF1
cooperates with both MyoD1 and myogenin to repress MuRF1 and MAFbx reporter gene
expression. These findings support the microarray data showing that both MAFbx and
MuRF1 expression remain elevated in MuRF1-null mice, suggesting that the MuRF1
gene product is necessary for returning atrogene expression to baseline levels following a
atrophic stimulus. Our findings suggest that MuRF1 acts as a modulator of myogenic
regulatory factors, although the exact mechanism is still unclear. Intriguingly, MuRF1
has been previously shown to regulate the localization of PPARα in cardiac muscle via
monoubiquitination providing a possible mechanism by which MuRF1 might impact
MRF function.14
While the exact mechanism of MuRF1 regulation of atrophy-responsive genes via
modulation of MyoD1 and myogenin is not yet known, there are multiple possible
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explanations. It is possible that MuRF1 serves to a) directly interact with MyoD1 and
myogenin and alter their function, stability or cellular localization, b) ubiquinate MyoD1
and myogenin as means to change their function, stability, or cellular localization, c)
target recruitment of additional transcription factors to the promoters of atrophy-induced
genes, or d) interact with or recruit additional proteins which themselves associate with
the promoters of muscle-specific genes.5
The latter possibility is of special interest given that recent research has shown
that many myogenic regulatory factors, including MyoD1 and myogenin, associate with
proteins such as HEB (TF12) and the E2A gene products E12 and E47. It has been well
established that members of the MyoD family of transcription factors, including MyoD1
and myogenin, function as heterodimers with more universally-expressed E proteins.
Multiple myogenic regulatory factors have been shown to associate with E proteins in a
sequential manner at numerous muscle-specific genes including muscle creatine kinase
(Ckm), desmin (Des), fast-twitch skeletal muscle troponin I, type 2 (Tnni2), leimodin 2
(lmod2), and titin cap (Tcap).5 While neither MuRF1 nor MAFbx were included in the
above study, we predict that these genes may also be regulated in part by the ubiquitously
expressed E proteins in association with MRFs, due to the presence of conserved E boxes
in both the MuRF1 and MAFbx proximal promoter. Interestingly, MuRF1-null mice
show differential gene expression in cardiac muscle, with a majority of the differentially
regulated genes being E2F regulated.35 The data presented in this research suggest that
MuRF1 gene expression may modulate the activity, recruitment, or stability of myogenic
regulatory factors and/or their known binding partners.
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While the exact mechanism of MuRF1-mediated repression of muscle-specific
genes through the potential modulation of MRFs remains less than complete, the data
presented here suggests that the RING domain of MuRF1 may be important.
Overexpression of the catalytically dead MuRF1 RING mutant in combination with
either MyoD1 or myogenin failed to cause any significant repression of the MuRF1
reporter gene. This suggests that ubiquitin tagging of MRFs by MuRF1 might be a
possible explanation for MuRF1-mediated regulation of MyoD1 and myogenin function
in muscle cells. It is also possible that MyoD1 and myogenin may recruit MuRF1 to the
promoters of target genes and allow for modification of other participants in the
transcriptional regulatory process. This MuRF1-mediated tagging may cause a change in
association and/or recruitment of the MRFs and/or their E protein binding partners to Ebox elements within target gene regulatory regions. This possibility is supported by our
data showing a complete loss of cooperative repression of the synthetic 4X-Ebox-SEAP
reporter when the MuRF1-RING mutant is over-expressed in combination with MyoD1
or myogenin. Furthermore, it is unlikely that potential MRF ubiquitin tagging catalyzed
by MuRF1 causes degradation of these transcription factors, as the level of myogenin
protein in cells overexpressing MuRF1 closely mirrors that seen in cells over-expressing
the MuRF1-RING mutant.
The catalytic RING domain of MuRF1 may participate in an array of functions in
addition to the interaction between MuRF1 and myogenic regulatory factors. Thus, there
are additional possible explanations for the data presented in this thesis. For example, the
loss of cooperative repression of the MuRF1 reporter construct and of the 4X-Ebox
reporter construct by MRFs and the MuRF1-RING mutant may also be explained by a
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change in the cellular localization of the MuRF1 protein following mutation. Previous
work has shown that the RING domain may function in nuclear localization of the
MuRF1 protein, likely through interaction with SUMO-3 (small ubiquitin-related
modifier-3,) which has itself been shown to participate in nuclear import.36,

37

Since it is

possible that mutation of the 3rd and 4th cysteine residues in the RING domain of MuRF1
may impact the localization of MuRF1 in the cell, future work to verify this possibility
will involve tagging the MuRF1 protein and the MuRF1-RING mutant with a GFP tag in
order to monitor cellular localization. Finally, in contrast to the RING domain, the acidic
c-terminal domain of MuRF1 is not suggested by this research to be integral to the
cooperation between MuRF1 and the myogenic regulatory factors in regulating gene
activity. This is supported by the observation that the 4X-Ebox and the MuRF1 reporter
constructs both show similar activity patterns in response to co-overexpression of the
MuRF1 c-term mutant or full-length MuRF1 with MyoD1 or myogenin. In summary, the
present study provides exciting new evidence supporting the hypothesis that MuRF1 may
act as a major transcriptional regulator of atrophy-induced gene expression. Specifically,
we demonstrate here that 1) MuRF1 acts as a transcriptional modulator of atrophyregulated genes, including itself, 2) MuRF1 does so in part via either direct or indirect
interactions with myogenic regulatory factors, and 3) specific domains of the MuRF1
gene product likely play an important roles in mediating this interaction.
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Conclusions and Future Directions
This thesis provides new evidence supporting the hypothesis that MuRF1 acts as a
major regulator in skeletal atrophy. Future work on this project should include
continued exploration of the potential interaction of MuRF1 with myogenic regulatory
factors and E proteins. It is conceivable that the synergistic repression of the MuRF1 and
MAFbx promoters by the combination of MuRF1 and MyoD1 or myogenin is mediated
by a ubiquitination effect by MuRF1. The stability and ubiquitination status of MyoD1,
myogenin, and associated E proteins could be evaluated via co-immunoprecipitation
experiments in cells that are over-expressing MuRF1 or the MuRF1-RING mutant.
Furthermore, immunoprecipitation of MyoD1 and myogenin from C2C12 cells that
ectopically express MuRF1 or MuRF1 RING mutant, followed by western blotting for
ubiquitin would help determine if MuRF1 is actually tagging these proteins in the cell.
In addition, future work using Chromatin Immunoprecipitations (ChIPs) of the
MuRF1 and MAFbx promoters with antibodies against MyoD1 and myogenin should be
performed in to explore the level of MRF occupancy of these promoters in response to
ectopic expression of MuRF1. Our preliminary research suggests that the degree of
myogenic commitment of the myoblast cells may play a large role in the effects of
MuRF1. Furthermore, MyoD1 and myogenin have recently been shown to transiently and
sequentially bind the promoters of other muscle-specific genes,5 suggesting that further
work should including exploration of this possible regulation its potential contribution to
cellular differentiation. Furthermore, MRF occupancy of the MuRF1 and MAFbx
promoters should be evaluated in response to ectopic expression of MuRF1 mutants, as
well as siRNA knockdown of MuRF1 in cells of varying stages of myogenic
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commitment. Finally, because skeletal muscle atrophy is a complex process and is
regulated on many levels, future work should extend beyond the exploration of the
transcriptional regulation of atrogenes by MuRF1. The analysis of the regulation of
MuRF1 on a post-transcriptional level would also likely yield important information
regarding the pathways of muscle plasticity.

Implications of this research
This research has allowed for a better understanding of the role that MuRF1 plays
in the regulation of muscle atrophy. A role of MuRF1 in the modulation of known muscle
regulatory factors suggests that MuRF1 plays a more global role in muscle dynamics than
has been previously thought. A better understanding of the regulation of MuRF1 has
added crucial pieces to the puzzle of MuRF1’s potential role in muscle metabolic control
mechanisms. There are also numerous aspects of interest to the clinician as well as to the
academic researcher, considering that MuRF1 has been implicated in numerous medical
pathologies. In addition to the well-documented effects during denervation and cachexia,
MuRF1 has also been recently implicated in muscle wasting associated with acute lung
injury.38 A better understanding of the regulation of MuRF1, and the regulation of other
muscle specific genes by MuRF1, is therefore of high interest.
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Chapter 3: Post-Transcriptional Regulation of MuRF1 and MAFbx

Overview
A continuation of the research described in this thesis will involve exploration of
the regulation of MuRF1 and MAFbx expression at additional genetic levels, namely at
the post-transcriptional level. Unlike the transcriptional regulation that directly activates
or represses gene promoters, post-transcriptional regulation often occurs after the DNA
has been transcribed by RNA Pol II into mRNA, but before the RNA has been translated
into a protein. This process is often mediated by microRNAs (miRNAs), which are
frequently localized to the untranslated region of mRNA at the 3’ end of the transcript
(3’UTR).39 Future work in this area will include an investigation into the effect of
extracellular signals such as Insulin-like Growth Factor-1 (IGF-1) and Transforming
Growth Factor-β (TGF-β) on the post-transcriptional regulation of MuRF1 and MAFbx
via miRNA signaling, since these pathways have been implicated in both microRNA
regulation and muscle tissue dynamics.40, 41

MuRF1 and MAFbx Have Long 3’ UTRs
Both MuRF1 and MAFbx have recently been revealed to have long and highly
conserved 3’UTRs. Because the majority of microRNA-mediated post-transcriptional
regulation occurs at the 3’ region of target mRNA molecules, MuRF1 and MAFbx are

50 | P a g e

good candidates for such regulation
regulation. The basic structure of a eukaryotic gene is shown
below in Figure 24.

Figure 24. Schematic of the Basic Structure of a Eukary
Eukaryotic Gene. (Open-access image)

In the figure shown above, the 3’UTR is illustrated at an approximately appropriate scale.
The median length of a eukaryotic 3’UTR is roughly 700bp
700bp, and this
his region is known to
affect the stability of the mRNA, translational efficiency, cellular localization,
polyadenylation, and often ccontains binding sites for miRNA.42,43
The Ensembl genetic database (www.ensembl.org) shows that MAFbx has an
unusually long 3’UTR. If the MAFbx 3’UT
3’UTR
R is indeed a conserved 5500 bp region of a
transcript totaling 7000 bp, then it is likely that the MAFbx 3’UTR may play
pl a significant
regulatory role. Furthermore, tthe MuRF1 3'UTR is predicted to be approximately 750 bp
in length. An analysis of the MuRF1 and MAFbx 3’UTR
3’UTRss by TargetScan,
(www.targetscan.org),, reveals sequences that may act as potential seed sites of known
miRNAs. The MuRF1 (Trim63) 3’UTR has potential binding sites for miR-23ab,
miR
miR29abc, miR-101,
101, and miR
miR-144 (Figure 25),
), while the MAFbx (Fbxo32) 3’UTR has
potential binding sites for miR
miR-144, miR-30, miR-23ab, and let-7
7 (Figure 26).
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Figure 25. MuRF1 3' UTR withh potential binding sites for known miRNAs
miRNAs.. (image from www.TargetScan.org)

Figure 26.. MAFbx 3’ UTR with potential binding sites for known miRNAs
miRNAs. (image from www.TargetScan.org)
www.TargetScan.org

MicroRNA Structure and Processing
The existence of potential binding sites for multip
multiple
le microRNAs (miRNAs) in the
3’UTRs
UTRs of both MuRF1 and MAFbx supports the hypothesis that there might be postpost
transcriptional mechanisms of regulation for both MuRF1 and MAFbx. miRNAs are a
focus of current interest in the field of molecular genetics, as they are highly prevalent,
participate in nearly every cellular process, and are predicted by bioinformatic analyses to
regulate roughly 60% of all protein
protein-coding genes.44 The discovery of miRNAs in
unicellular organisms indicated that they have a much more ancient evolutionary origin
than has been previously though
thought, and they have recently been shown to play a significant
role in muscle atrophy.45,46
MicroRNAs
RNAs are roughly 21 nucleotide
nucleotide-long
long RNA molecules that regulate gene
expression. As seen below in Figure 27,, miRNAs are initially transcribed as long primiRNA molecules.
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Image redacted, paper copy available
upon request to home institution.

Figure 27. The Biogenesis of MicroRNA molecules. (open-access image)

These large molecules are then processed in the nucleus by the RNase complex Drosha
into smaller stem-loop
loop miRNA precursors called pre
pre-miRNA.47 These pre-miRNA
molecules are then exported from the nucleus by Exportin
Exportin, and cleaved in the cytoplasm
into mature miRNAs by the RNase complex Dicer.48 One of the strands
strand of doublestranded mature miRNA is incorporated into the RNA
RNA-Induced Silencing
lencing Complex
(RISC) and the other strand is degraded.49 This complex effectively targets
complementary seed sequences in target mRNA molecules.. The subsequent inhibition of
the translation of mRNA to protein, or the de-polyadenylation
adenylation and subsequent decay of
mRNA both serve to negatively regulate target genes.50
The role of miRNAs in muscle remodeling is of increasing interest. Recent
research has shown miRNAs, such as miR-23a,
23a, promote resistance to glucocorticoidglucocorticoid
induced muscle atrophy, while concurrently repressing the translation of MuRF1 and
MAFbx through their 3’UTRs.46 Other research has shown miRNAs to be involved in the
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processes of muscle myoblast differentiation by targeting muscle-specific transcription
factors such as myogenin and MyoD1 activate genes that induce myoblasts to retreat
from the cell cycle and ultimately fuse into multi-nucleated myotubes.51 Additionally,
TGF-β, a known inducer of skeletal muscle atrophy, and IGF-1, a known inducer of
muscle hypertrophy, both have been shown to affect miRNA expression in skeletal
muscle.40 Consequently, the role of TGF-β and IGF-1 in miRNA-mediated regulation of
MuRF1 and MAFbx is a potential avenue of continued exploration in our lab.

IGF-1 and TGF-β Signaling Pathways Regulate Skeletal Muscle Dynamics
IGF-1 and TGF-β play important regulatory roles in skeletal muscle hypertrophy,
atrophy and fibrosis. Furthermore, these growth factors have been shown to impose their
regulatory effects of muscle-specific gene expression at the post-transcriptional and
transcriptional levels. For example, Insulin-like growth factor-1 (IGF-1) has been shown
to induce muscle hypertrophy via the PI3K-Akt-FoxoO pathway leading to decreased
MuRF1 and MAFbx expression (Figure 28).52
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Image redacted, paper copy available upon
request to home institution.

Figure 28.. Schematic of the TGF
TGF-β and IGF-1 Signaling Pathways.

53

Furthermore, the
he over
overexpression of IGF-1
1 in mice causes an increase in muscle
mass and cross-sectional
sectional area (CSA).54 Conversely, the knock-down
down of the IGF-1
IGF
receptor causes a loss of muscle mass and CSA.55 The binding of IGF-1
IGF ligand to its
corresponding receptor activates a cascade of events ultimately leading to protein
synthesis,
nthesis, as shown in Figure 28.53 In addition, IGF-1 and miRNAs reciprocally regulate
each other in skeletal muscle
muscle, suggesting that IGF-1
1 may transcriptionally regulate
miRNA expression, leading to dow
downstream and indirect post-transcriptional
transcriptional regulation of
muscle-specific genes.41
Like the muscle hypertrophy pathways, the muscle atrophy pathways are also
highly regulated processes, which involve cross-talk with the synthesis pathway
described above, providing another potential link to regulation of MuRF1 and MAFbx
expression. A significant amount of research involves characterization of myostatin, a
member of the TGF-ββ superfamily
superfamily,, but recent research has shown that Transforming
growth factor-β1 (TGF-β1
β1) may also play an important role in skeletal muscle function.
function
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TGF-β1 is a well characterized cytokine that promotes the proliferation of fibroblast
cells, causes fibrosis and inflammation, and is associated with many diseases of skeletal
muscle.56-58 TGF-β1 also regulates microRNAs that influence skeletal muscle
differentiation.59 Because TGF-β1 has been implicated in skeletal muscle wasting and
fibrosis, this research also currently involves the exploration of the miRNA-mediated
mechanism by which it may affect MuRF1 and MAFbx expression.
Interestingly, MAFbx expression levels and muscle protein ubiquitination have
been demonstrated to increase quickly following TGF-β1 administration, but the
molecular mechanisms behind the TGF-β1-mediated effects on MAFbx expression are
not yet fully understood.60,

61

TGF-β1 has also been previously shown to alter muscle

plasticity via modulation of miR-29, and recently it has been determined that this effect is
mediated, at least in part, by Smad3 inhibition of MyoD1 binding to the miR-29
promoter.62 Future research will focus closely on the role of TGF-β1 in the posttranscriptional regulation of MuRF1 and MAFbx.
Finally, IGF-1 has also been shown to block upregulation of MuRF1 and MAFbx,
in part, through the inhibition of myostatin.63 Myostatin, a member of the TGF-β
superfamily of genes, phosphorylates and thus activates Smad3, which then regulate
downstream genes, including MuRF1 and MAFbx.63 The mediation of Smad3 via TGFβ1 and IGF-1 on MuRF1 and MAFbx expression has beeen explored further in our lab,
with a focus on the role of miRNAs in this process.
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Materials and Methods

Cloning of the 3’UTRs of MuRF1 and MAFbx
The MuRF1 and MAFbx 3’UTRs were analyzed using the Ensembl database
(www.ensembl.org). The following primers were designed to amplify ~750 bp of the
MuRF1 3’UTR and ~1300 bp of the MAFbx UTR:
MuRF1 FWD: 5’-GC-GAGCTC-AGA AGG AGA TGA GTG AGA CAC GC-3’
MuRF1 REV: 5’-GC-AAGCTT-GAG GCA GAG TCT CTC TAT GTA GC-3’
MAFbx FWD: 5’-GC-GAGCTC-AT AAT CCC AGC ACA CGA ACA CAC TTC AG3’
MAFbx REV: 5’-GC-AAGCCT -GTT TGC CAA GAG CAT GCA TAG TGG C-3’
These primers were used in an RT-PCR reaction that consisted of PCR buffer,
dNTP mixture, 1.5 mM MgCl2, forward and reverse primers, 2.0 µL of RT-reaction, and
Taq polymerase diluted in nuclease-free water. The cycling conditions were 94°C for 2
min, followed by 30 cycles of 94°C for 45 sec, 55°C for 1 min, and 72°C for 1.5 minutes,
a final extension at 72° for 10 min and then held at 10°C until the reactions were
removed from the thermocycler. Following PCR, the products were electrophoresed on a
0.7% agarose gel, purified via a commercial purification protocol (Qiagen, Valencia,
CA,) and cloned into the pMIR-Report luciferase reporter plasmid (Promega, Madison,
WI).
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Construction of 3'UTR-SEAP-Reporter Plasmids
Pilot transfection experiments were performed in C2C12 myoblast cells with little
luciferase activity recorded, so an alternative approach was designed. The 1500 bp
sequence of secreted alkaline phosphatase cDNA from the pSEAP2-Basic plasmid was
amplified by PCR and cloned into the pMIR-Report reporter plasmid, lacking the
luciferase coding region. Briefly, the 1500 bp sequence of the pSEAP2-Basic plasmid
corresponding to the secretion of alkaline phosphatase was amplified via PCR using
primers containing restriction enzyme sites for Bgl II in the forward primer and SpeI in
the reverse primer. The PCR product was then run on a 0.7% gel and purified as
previously described. The previously-designed pmir-Report plasmids with the MuRF1
and MAFbx 3’UTRs were digested with Bam HI and Spe I in order to remove the
luciferase cDNA from the pMIR-Report plasmid. The 1500 bp SEAP fragment was then
ligated into the linearized MuRF1-3’UTR-pMIR-Report and the MAFbx-3’UTR-pMIRReport plasmids lacking the luciferase gene. This effectively formed two original
plasmids with either the MuRF1 3’UTR or the MAFbx 3’UTR fused to the SEAP gene,
(MuRF1-SEAP-Report and MAFbx-SEAP-Report, respectively) which are well suited
for analysis in C2C12 cells.

SEAP Reporter Assays
The activities of the newly designed MuRF1-SEAP-Report and MAFbx-SEAPReport plasmids were preliminarily tested in mouse myoblast cells. The MuRF1-SEAPReport plasmid and the MAFbx-SEAP-Report plasmid was transfected into C2C12 cells
as described previously. Following a 24 hr incubation at 37°C at 6% CO2, the C2C12 cells
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were then treated with either 100 pM TGF-β1, 100 ng/ml IGF-1. 1 µM Dexamethasone,
or a control solution containing only DMEM media. The levels of secreted alkaline
phosphatase and corresponding plasmid activities were measured at 24 hr intervals using
a commercial SEAP protocol as described previously in Chapter 2.

siRNA Knockdown
siRNA knockdown of Smad3 was performed to further illustrate the role this gene
plays in the atrophy process. This was accomplished through the use of the pSupersiRNA System (OligoEngine), which uses a mammalian expression vector that allows for
the transcription of short RNA transcripts such as siRNAs.
Oligonucleotide sequences were designed to correspond exactly to identified
nucleotide sequences identified in the mRNA transcript of Smad3. Two unique sequences
for targeting Smad3 were designed, phosphate end-labeled with T4 Polynucleotide
Kinase, annealed, cloned into the pSuper plasmid and sequenced to confirm lack of
mutations. The sequences used were:
Smad3 Set1

5’ GATCCCC ACT TTC TAC TGC CAC TTG G TTCAAGAGA C CAA GTG GCA GTA GAA AGT TTTT TC

3’

3’

5’

GGG TGA AAG ATG ACG GTG AAC C AAGTTCTCT G GTT CAC CGT CAT CTT TCA AAAA AGAGCT

Smad3 Set2
5’ GATCCCC GTT CTC CAG AGT TAA AAG C TTCAAGAGA G CTT TTA ACT CTG GAG AAC TTTT TC
3’

3’

GGG CAA GAG GTC TCA ATT TTC G AAGTTCTCT C GAA AAT TGA GAC CTC TTG AAAA AGAGCT 5’

The resulting pSuper plasmids were transfected with the SEAP-MAFbx-Report plasmid
or the SEAP-MuRF1-Report plasmid into C2C12 cells as described previously. A pSupernull plasmid, similarly designed but containing no inhibitory sequences, was used as a
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negative control. The effects of Smad3 knockdown on the activity of the SEAP-MAFbxReport and SEAP-MuRF1-Report plasmids were then analyzed using a commercial
SEAP protocol as previously described.

Preliminary Results
As seen below in Figure 29, the MAFbx-SEAP-Report and the MuRF1-SEAPReport reporter constructs were successfully engineered and both showed quantifiable
expression levels following transfection into C2C12 cells. The activity of the constructed
SEAP-Report plasmids containing either the MuRF1 3’UTR or MAFbx 3’UTR showed a
marked increase in activity at 72 hrs when compared to the control SEAP-Report-null
plasmid after treatment with TGF-β1, while IGF-1 had no effect on reporter activity.

250000

RLU (+/- SD)

200000
no treatment
150000
100000
50000

+ TGF-B
+ IGF1

0

Figure 29. The MAFbx-SEAP-Report and MuRF1-SEAP-Report plasmids show an increase in expression in cells
treated with TGF-β1. C2C2 myoblasts were transfected with the MAFbx-SEAP-Report plasmid, the MuRF1-SEAPReport plasmid, or a control plasmid consisting of only the empty SEAP-Report plasmid, and a β-galactosidase
expression plasmid. The cells were treated with either TGF-β1, IGF-1, or DMEM as a negative control. The myoblasts
were maintained in standard culture media. Samples of media were taken at 72 hrs and measured for SEAP activity.
The samples were normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each
condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean.
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Furthermore, since dexamethasone is a synthetic glucocorticoid that is known to induce
muscle atrophy, the activities of the MuRF1 and MAFbx 3’-UTR reporter constructs
were analyzed in cells transfected with the glucocorticoid receptor and treated with
dexamethasone. The data revealed no significant change in activity of the SEAP-null
plasmid when treated with dexamethasone, however there was a marked increase in
activity of both the SEAP-Report-MuRF1-3'UTR plasmid or the SEAP-Report-MAFbx-

RLU (+/- SD)

3'UTR after treatment with dexamethasone (Figure 30).
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Figure 30. The MAFbx-SEAP-Report and MuRF1-SEAP-Report plasmids show increased expression when treated
with Dexamethasone. C2C12 myoblasts were transfected with the MAFbx-SEAP-Report reporter, the MuRF1-SEAPReport reporter, or a control plasmid consisting of only the empty SEAP-Report plasmid, and a β-galactosidase
expression plasmid. The cells were treated with either dexamethasone or DMEM as a negative control. The myoblasts
were maintained in standard culture media. Samples of media were taken at 72 hrs and measured for SEAP activity.
The samples were normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each
condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean.

Finally, since Smad3 has been linked to several miRNA-mediated mechanisms of
regulation, preliminary work has also involved investigating the effects of Smad3
knockdown on MuRF1 and MAFbx 3'UTR reporter plasmid activity. To test the role of
Smad3 in MAFbx expression, activity of the MAFbx-SEAP-Report and MuRF1-SEAPReport plasmids were compared to that of an empty control SEAP-Report plasmid with
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no UTR, under conditions of Smad3 knockdown. Smad3 knockdown was accomplished
by using either the Smad3-pSuper-siRNA expression plasmid or a control pSuper
plasmid lacking an siRNA insert. The empty SEAP-Report-null plasmid showed no
significant differences in activity in normal cells compared to Smad3-knockdown cells,
while the MAFbx-3’UTR-SEAP-Report and MuRF1-3'UTR-SEAP-Report reporter
construct showed a significant increase in activity in Smad3 knockdown cells compared
to normal cells (Figure 31).
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Figure 31. The MuRF1-SEAP-Report and MAFbx-SEAP-Report plasmids show an increase in expression in Smad3
knockdown cells. C2C12 myoblasts were transfected with a reporter construct consisting of the MAFbx-SEAP-Report
plasmid, MuRF1-SEAP-Report plasmid or a negative control plasmid consisting of only the empty SEAP-Report
plasmid, and a β-galactosidase expression plasmid. The cells had previously been transfected with either pSuperSmad3 siRNA, or an empty pSuper expression plasmid. The myoblasts were maintained in standard culture media.
Samples of media were taken at 72 hrs and measured for SEAP activity. The samples were normalized to βgalactosidase activity to correct for variation in transfection efficiency. Each condition was done in triplicate and the
error bars represent standard deviation (-/+ S.D.) of the mean.
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Future Work:
In light of the above preliminary results, future work will involve continued
exploration of the post-transcriptional regulation of MuRF1 and MAFbx with respect to
Smad3-mediated miRNA activity. A bioinformatics approach was undertaken to further
characterize the potential contribution of miRNA in the regulation of MuRF1 and
MAFbx. The TargetScan database (www.TargetScan.org) was used to identify putative
binding sites for miRNAs in the 3’UTRs of MuRF1 and MAFbx. miR-23 and mir-144
were identified as having binding sites present in the 3'UTRs of both MuRF1 and
MAFbx, suggesting possible common patterns of regulation by these miRNAs. mir-23
has already been shown to play a role in muscle development, while miR-144 has
recently been shown to be differentially expressed in aging muscle.64, 65 Thus, future work
on this project should focus on these miRNAs.
Reporter assays using the MuRF1-3'UTR-SEAP-Report or MAFbx-3'UTRSEAP-Report plasmids should be performed with the simultaneous overexpression of
miRNA-23 and/or miRNA-144 to determine if these microRNAs can alter the expression
of the MuRF1 and MAFbx 3’-UTR reporter plasmids. Additionally, the introduction of
anti-miRNA locked nucleic acids (LNAs) should be used to reverse these miRNA effects.
LNAs are nucleic acid analogs in which the ribose ring is locked with a methylene bridge
connecting the 2'-oxygen atom with the 4'-carbon within the ring. These LNAs bind to,
and effectively inhibit, complementary microRNAs. The combination of experiments
involving the overexpression of specific miRNAs with experiments involving specific
miRNA inhibition, will allow us to determine with confidence that these microRNAs
bind to the UTRs of MuRF1 and MAFbx.
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Finally, in order to further examine post-transcriptional regulation of MuRF1 and
MAFbx, this project will eventually compare levels of MuRF1 and MAFbx protein
production following deletion of the 3’UTRs of these genes. If the levels of protein
produced differ following deletion of the 3’UTR, then a post-transcriptional mechanism
of regulation may be implicated. In order to address these questions, the cDNA molecules
lacking the 3'UTRs of MuRF1 and MAFbx have been cloned. These genes have been
tagged with myc, which is polypeptide protein tag, and cloned into expression plasmids.
Future work will also involve cloning the MuRF1 and MAFbx cDNA with their 3'UTRs,
tagging them with myc, and inserting them into an expression plasmid. These plasmids
containing myc-tagged MuRF1 and MAFbx with or without their 3'UTRs will then be
transfected into C2C12 cells that will be subsequently treated with or without TGF-β1,
IGF-1, or Dexamethasone. The cells will then be homogenized and proteins lysates will
be used for Western Blotting to detect MuRF1 and MAFbx protein levels in order to
determine in changes in protein production that may result due to changes in miRNA
expression mediated by growth factor treatments.
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